Butalbital, Acetaminophen, Caffeine and Codeine Phosphate
Butalbital, Acetaminophen, Caffeine and Codeine Phosphate is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Butalbital, Acetaminophen, Caffeine and Codeine Phosphate; Generic name: BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE; Drug class: Barbiturate [EPC].
| Brand name | Butalbital, Acetaminophen, Caffeine and Codeine Phosphate |
|---|---|
| Generic name | BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE |
| Drug class | Barbiturate [EPC] |
| Manufacturer | Bryant Ranch Prepack |
| Used for | 1 INDICATIONS AND USAGE Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules are indicated for the management of the symptom complex of tension (or muscle contraction) headache when non-opioid analgesic and alternative treatments are inadequate. Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsule is a combination product of butalbital, a barbiturate; acetaminophen; caffeine, a methylxanthine; and codeine phosphate, an opioid agonist; and is indicated for the management of the symptom complex of tension (or muscle contraction) headache, when other non-opioid analgesic and alternative treatments are inadequate. ( 1 ) Limitations of Use Because of the risks of addi |
| Dosage | 2 DOSAGE AND ADMINISTRATION Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals. ( 2.1 ) Individualize dosing based on the severity of pain, patient response, prior analgesic experience, and risk factors for addiction, abuse, and misuse. ( 2.1 ) Discuss availability of naloxone with the patient and caregiver and assess each patient's need for access to naloxone, both when initiating and renewing treatment with Butalbital, Acetaminophen, Ca |
| Warnings | WARNING: ADDICTION, ABUSE, AND MISUSE; RISK EVALUATION AND MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; ULTRA-RAPID METABOLISM OF CODEINE AND OTHER RISK FACTORS FOR LIFE-THREATENING RESPIRATORY DEPRESSION IN CHILDREN; NEONATAL OPIOID WITHDRAWAL SYNDROME; INTERACTIONS WITH DRUGS AFFECTING CYTOCHROME P450 ISOENZYMES; and HEPATOTOXICITY WARNING: ADDICTION, ABUSE, AND MISUSE; RISK |
| Active ingredient(s) | ACETAMINOPHEN |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15a34df5-e48f-4570-9232-80e4093c4624 |